Kim, Jaegil
Mouw, Kent W
Polak, Paz
Braunstein, Lior Z
Kamburov, Atanas
Tiao, Grace
Kwiatkowski, David J
Rosenberg, Jonathan E
Van Allen, Eliezer M
D'Andrea, Alan D
Getz, Gad
Article History
Received: 8 July 2015
Accepted: 1 April 2016
First Online: 25 April 2016
Competing interests
: J.E.R. and E.M.V.A. have a patent pending for use of <i>ERCC2</i> mutational status as a predictive biomarker for cisplatin sensitivity.